Literature DB >> 16594735

Interactions between leukotriene C4 and interleukin 13 signaling pathways in a mouse model of airway disease.

Jaime Chavez1, Hays W J Young, David B Corry, Michael W Lieberman.   

Abstract

CONTEXT: During an asthmatic episode, leukotriene C4 (LTC4) and interleukin 13 (IL-13) are released into the airways and are thought to be central mediators of the asthmatic response. However, little is known about how these molecules interact or affect each other's signaling pathway.
OBJECTIVE: To determine if the LTC4 and IL-13 signaling pathways interact with each other's pathways.
DESIGN: We examined airway responsiveness, cysteinyl LTs (Cys-LTs), and Cys-LT and IL-13 receptor transcript levels in wild-type mice and in mice that were deficient in gamma-glutamyl leukotrienase (an enzyme that converts LTC4 to LTD4), STAT6 (signal transducer and activator of transcription 6 [a critical molecule in IL-13 signaling]), and IL-4Ralpha (a subunit of the IL-13 receptor).
RESULTS: Wild-type (C57BL/129SvEv) and gamma-glutamyl leukotrienase-deficient mice showed increased airway responsiveness after intranasal instillation of IL-13; similar results were observed after intranasal instillation of IL-13 or LTC4 in a second wild-type strain (BALB/c). Interleukin 13 treatment reduced levels of Cys-LTs in bronchoalveolar lavage fluid. This change was unaccompanied by changes in other arachidonic acid metabolites or in RNA transcript levels of enzymes associated with Cys-LT synthesis. Interleukin 13 treatment also increased transcript levels of the Cys-LT 1 and Cys-LT 2 receptors, while LTC4 increased transcript levels of the alpha1 chain of the IL-13 receptor. Furthermore, IL-4Ralpha-deficient mice had increased airway responsiveness to LTC4 but not to IL-13, whereas STAT6-deficient mice failed to respond to either agonist.
CONCLUSIONS: These findings indicate that LTC4 and IL-13 are dependent on or signal through STAT6 to increase airway responsiveness and that both agonists regulate expression of each other's receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16594735     DOI: 10.5858/2006-130-440-IBLCAI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

1.  Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma.

Authors:  Tengfei Zhang; Kamal Srivastava; Ming-Chun Wen; Nan Yang; Jing Cao; Paula Busse; Neil Birmingham; Joseph Goldfarb; Xiu-Min Li
Journal:  Phytother Res       Date:  2010-07       Impact factor: 5.878

2.  Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production.

Authors:  Taylor A Doherty; Naseem Khorram; Sean Lund; Amit Kumar Mehta; Michael Croft; David H Broide
Journal:  J Allergy Clin Immunol       Date:  2013-05-17       Impact factor: 10.793

Review 3.  Etiology of exercise-induced asthma: physical stress-induced transcription.

Authors:  Thomas Hilberg
Journal:  Curr Allergy Asthma Rep       Date:  2007-04       Impact factor: 4.806

4.  Unveiling the roles of the glutathione redox system in vivo by analyzing genetically modified mice.

Authors:  Junichi Fujii; Jun-Itsu Ito; Xuhong Zhang; Toshihiro Kurahashi
Journal:  J Clin Biochem Nutr       Date:  2011-06-03       Impact factor: 3.114

5.  Leukotriene enhanced allergic lung inflammation through induction of chemokine production.

Authors:  Kihyuk Shin; Jung Joo Hwang; Bo-In Kwon; Farrah Kheradmand; David B Corry; Seung-Hyo Lee
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 5.057

Review 6.  Clinical and Translational Significance of Basophils in Patients with Cancer.

Authors:  Jitesh Chauhan; Chara Stavraka; Melanie Grandits; Lais C G F Palhares; Debra H Josephs; Katie E Lacy; James Spicer; Heather J Bax; Sophia N Karagiannis
Journal:  Cells       Date:  2022-01-27       Impact factor: 7.666

7.  Interleukin-13 signaling and its role in asthma.

Authors:  Efren L Rael; Richard F Lockey
Journal:  World Allergy Organ J       Date:  2011-03       Impact factor: 4.084

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.